NEW YORK, Sept. 28, 2016 /PRNewswire/ -- MatriTek, Inc., a product-oriented biotechnology company specializing in tissue-specific cell culture biomaterials, announced today the launch of commercial production of novel extracellular matrix (ECM) biomaterials for biomedical research.
MatriTek's proprietary TissueSpec™ platform technology enables scientists to culture cells in a physiologically relevant extracellular microenvironment and is coupled with the company's core expertise in cell and tissue culture biomaterials and in-vitro models for biomedical research. MatriTek's novel ECM biomaterials are fully customized to address research needs in cell biology, stem cell and cancer research, and regenerative medicine.
MatriTek's cutting-edge technology was developed by a team led by Dr. Gordana Vunjak Novakovic, Mikati Foundation Professor of Biomedical Engineering and Professor of Medical Sciences at Columbia University, demonstrating the potential for a broad range of applications in stem cell research and regenerative medicine. Dr. Vunjak Novakovic is a renowned expert in tissue engineering and a member of the American Institute for Medical and Biological Engineering, Academia Europaea, National Academy of Engineering, National Academy of Medicine, and National Academy of Inventors.
"I am really excited about launching MatriTek's line of tissue-specific cell culture products, as they fulfill the long-standing need for culturing cells in a native-like environment," said Dr. Gordana Vunjak Novakovic. "These extracellular matrix biomaterials could have a major impact on studies of cells and tissues in the context of development, regeneration, and the modeling of disease."
"It's the simple idea of mimicking nature. MatriTek was created to address the needs of life science researchers for natural, physiological microenvironments in which to grow and study cells and tissues," said John O'Neill, MatriTek co-founder and lead inventor. "Extracellular matrix, a major component of tissues, supports and regulates cell growth and tissue function. Our team has isolated and validated a number of widely used tissue-specific matrices that provide native physiological conditions as well as signaling and regulatory functions highly specific to each tissue."
"We are so pleased that MatriTek is bringing this technology platform to market," commented Beth Kauderer from Columbia Technology Ventures, the technology transfer office at Columbia University, "as we believe the platform will have important applications in oncology, neuroscience, pharmacology, toxicology, regenerative medicine, and other fields.
MatriTek, Inc. is headquartered in New York City with production and R&D facilities at the Alexandria Center for Life Science.
"MatriTek continues to evolve and advance its TissueSpecTM platform with a focus on research needs in the life sciences," said Ljiljana Kundakovic, Chief Executive Officer of MatriTek. "We are taking critical steps to ensure that MatriTek's technology and development capabilities are made available to scientists worldwide."
About MatriTek, Inc.
MatriTek, Inc. is a biotechnology company that specializes in the production of tissue-specific extracellular matrix biomaterials for use in life sciences research to provide physiologically relevant cell culture microenvironments that can be applied to challenging problems across biomedical research. MatriTek products have the potential to foster translation of science to new treatments and therapies and drive scientific discovery in stem cell and cancer research and regenerative medicine.
About the Alexandria Center for Life Science – New York City
Alexandria Real Estate Equities, Inc. developed the Alexandria Center for Life Science, New York City's first and only world-class commercial life science campus. The approximately 728,000 rentable square feet campus features two Class A office/laboratory buildings and a variety of creative amenities. The East and West Towers are both LEED® Gold and Wired Certified Platinum, exemplifying Alexandria's commitment to providing its tenants with sustainable campuses on the cutting edge of technology. From multinational pharmaceutical companies, including Eli Lilly and Company, Pfizer Inc. and Roche, to early-stage companies spinning out of Accelerator Corporation, the campus has become the epicenter for scientific and technological innovation in New York City.
For more information, please visit matritek.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/matritek-launches-commercial-operations-at-the-alexandria-center-for-life-science-in-new-york-city-300335764.html
SOURCE MatriTek, Inc.